FloridaTaper

Category: Iatrogenic Injury

  • Gabapentin Dependence: The Overlooked Deprescribing Challenge

    Gabapentin Dependence: The Overlooked Deprescribing Challenge

    Gabapentin is prescribed for an expanding list of conditions: neuropathic pain, partial seizures, fibromyalgia, restless legs, anxiety, insomnia, alcohol withdrawal, and opioid-sparing postoperative analgesia. The prescribing profile has grown considerably faster than the evidence base, and the drug’s reputation as a benign, non-controlled alternative to benzodiazepines and opioids has produced a cohort of patients who are physically dependent on gabapentin with little recognition of that fact by their prescribers.

    The word “dependence” here is narrow. Gabapentin has modest abuse potential — particularly in polysubstance users, particularly at supratherapeutic doses — but that is not the common clinical problem. The common problem is iatrogenic physical dependence in patients taking prescribed doses, who cannot stop the medication without significant withdrawal symptoms and who are rarely warned that this is possible.

    Pharmacology, Briefly

    Despite its name, gabapentin does not act directly on GABA-A receptors. It binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing presynaptic calcium influx and attenuating excitatory neurotransmitter release — particularly glutamate, but also norepinephrine and substance P. This mechanism underlies its analgesic, anxiolytic, and anticonvulsant effects. The relevance to dependence is that chronic suppression of calcium channel function produces compensatory adaptations; when the drug is removed, the channel activity rebounds, producing a state that clinically resembles benzodiazepine withdrawal in many features.

    Recognizing Physical Dependence

    Physical dependence on gabapentin emerges on a predictable timescale — usually weeks to a few months of consistent dosing. Patients do not typically describe it as dependence; they describe the following.

    Rebound symptoms when a dose is missed or delayed. Anxiety, irritability, insomnia, headache, or return of the original pain complaint within 12 to 24 hours of a missed dose.

    Dose-inflexibility. Attempts to lower the dose produce symptoms that the patient interprets as return of the underlying condition, leading back to the original dose.

    New symptoms on stable dose. Some patients develop a syndrome that resembles tolerance: anxiety, insomnia, restless sensations, or cognitive symptoms that were not present at baseline and are incompletely relieved by the next dose.

    The Withdrawal Syndrome

    Acute gabapentin withdrawal in a physically dependent patient can include anxiety, insomnia, tremor, sweating, nausea, headache, palpitations, and restlessness. Reports of withdrawal seizures exist, particularly after abrupt discontinuation of high-dose regimens. In patients with histories of benzodiazepine exposure or other GABA-system involvement, the withdrawal picture can be indistinguishable from benzodiazepine withdrawal, which makes separating cause and contribution difficult when the two medications are being tapered simultaneously.

    A protracted course has been described but is less well characterized than in benzodiazepines. Some patients report months of residual symptoms after discontinuation, including heightened sensory sensitivity and autonomic features.

    Why Deprescribing Is Overlooked

    Several structural factors contribute.

    The first is the prescribing context. Gabapentin is often added opportunistically — to manage pain during a benzodiazepine taper, to address insomnia from SSRI withdrawal, to provide an opioid-sparing adjunct after surgery — with no exit strategy defined. The initial prescription tends to become the chronic prescription.

    The second is the drug’s low-profile reputation. Because gabapentin is not federally scheduled (it is controlled in some states; pregabalin carries Schedule V status federally), prescribers treat it as low risk and rarely initiate a deprescribing conversation.

    The third is diagnostic confusion. When a patient’s attempt to reduce gabapentin produces anxiety and insomnia, the default interpretation is that the original indication has returned and requires continued treatment. The withdrawal framework is often not considered.

    How to Approach Deprescribing

    The principles parallel what the Ashton Manual and Maudsley Deprescribing Guidelines (Horowitz and Taylor, 2024) recommend for benzodiazepines, with some adjustments specific to gabapentin pharmacology.

    Slow taper. Reductions of 10% per month from current dose, with smaller reductions as the dose falls, are well tolerated by most patients. Faster protocols sometimes work in short-exposure patients; slower protocols are needed for patients with years of use or concurrent benzodiazepine exposure.

    Dose redistribution before reduction. For patients on twice-daily dosing, shifting to three-times-daily dosing before starting reductions can reduce interdose symptoms and make subsequent reductions more tolerable.

    Liquid or compounded formulations at lower doses. Once the dose is below 300 mg daily, tablet strengths limit precision, and a compounded liquid allows smooth reductions.

    Parallel tapers with caution. If a patient is tapering both a benzodiazepine and gabapentin, the usual recommendation is to taper one at a time rather than both simultaneously. Which to do first depends on the clinical picture and the symptoms driving the decision, but running both tapers in parallel multiplies the withdrawal burden in a way most patients cannot sustain.

    Hold through flares. Dose holds during symptom exacerbations work in the same way they do for benzodiazepines — buying time for the nervous system to adapt before the next reduction.

    Gabapentin Added During a Benzodiazepine Taper

    A specific clinical question is whether gabapentin should be added during a benzodiazepine taper to manage withdrawal symptoms. The short answer is: rarely, and not without a deprescribing plan defined before the first dose is given.

    Adding gabapentin to a benzodiazepine taper can produce short-term symptom relief. It also produces a new dependence with its own withdrawal course, and the patient then faces two tapers instead of one. For some patients — particularly those with intractable neuropathic pain or seizure disorders — the trade-off may still be favorable. For most, it is not.

    Patients who find themselves on gabapentin that was added during a prior benzodiazepine taper, and who are now facing the gabapentin taper as a second problem, are a recognizable clinical population. The solution is not to accelerate either taper but to complete them sequentially, with adequate time for stabilization between.

    What to Ask For

    Patients who suspect they may be physically dependent on gabapentin can raise the question directly with their prescriber. Useful framings: “I’d like to understand what happens if I stop this medication,” “what is the deprescribing plan,” and “what would a slow taper look like.” The absence of a clear answer to these questions is itself useful information.

    Gabapentin dependence is a clinical reality that the current prescribing culture around the drug does not reliably recognize. Addressing it requires treating gabapentin with the same care that benzodiazepines are increasingly receiving — which is to say, acknowledging that long-term use produces adaptations, and that removal requires planning.

  • Kindling and Benzodiazepines: Why Failed Tapers Make the Next One Harder

    Kindling and Benzodiazepines: Why Failed Tapers Make the Next One Harder

    Kindling, in the addiction and withdrawal literature, refers to the phenomenon in which repeated cycles of withdrawal produce progressively worse withdrawal syndromes on each subsequent cycle. The mechanism was first characterized in alcohol dependence by Robert Post and others in the 1980s, where the observation was clinical and unambiguous: patients with histories of multiple detoxifications from alcohol had more severe, more medication-resistant, and more seizure-prone withdrawal courses than patients undergoing a first detox. The same framework, with stronger and weaker evidence depending on the specific claim, has been extended to benzodiazepines.

    For patients who have attempted and failed one or more benzodiazepine tapers, this matters. Each failed attempt may not be a neutral event; the preliminary evidence suggests that the next attempt is starting from a harder place than the first.

    What Kindling Actually Describes

    Two overlapping phenomena are usually bundled under the term.

    The first is neuronal sensitization. Repeated withdrawal episodes produce lasting changes in excitatory and inhibitory neurotransmission that lower the threshold for symptom emergence and seizure on subsequent withdrawals. The word “kindling” is borrowed from the experimental model in which repeated subthreshold electrical stimulation of the amygdala eventually produces spontaneous seizures at intensities that were originally subthreshold. The withdrawal application extends this: repeated subthreshold excitatory episodes — withdrawal-induced hyperexcitability — produce durable changes in the circuitry’s response to subsequent insults.

    The second is behavioral or affective sensitization. Each withdrawal episode produces more severe subjective symptoms than the last, independent of any measurable seizure threshold. Patients report that a second or third attempt at a taper is “not just the first withdrawal again” but is qualitatively more intense, more protracted, and more refractory to standard symptom management.

    The Evidence in Benzodiazepines

    The kindling literature in benzodiazepines is not as robust as in alcohol, but several lines of evidence converge.

    Animal work demonstrates that repeated withdrawal from chronic benzodiazepine administration produces increasing signs of withdrawal severity and, in some paradigms, reductions in GABA-A receptor function beyond what single-cycle withdrawal produces.

    Clinical observation, accumulated across decades of case series and the Ashton Manual’s patient cohorts, describes a recognizable pattern in which patients who have attempted rapid detox, or who have cycled off and back on benzodiazepines multiple times, present with withdrawal courses that are unusually severe and prolonged relative to their total benzodiazepine exposure.

    The overlap with patients who later develop features consistent with benzodiazepine-induced neurological dysfunction (BIND) is notable. Ritvo and colleagues’ 2023 description of BIND includes multiple withdrawal attempts as a feature in a meaningful proportion of the reported cohort.

    The mechanism is not fully characterized. Candidates include glutamatergic upregulation, persistent alterations in GABA-A receptor subunit composition, secondary neuroinflammation, and HPA axis changes. Whichever mechanism or combination is operative, the clinical implication is the same: the safest number of taper attempts is one successful one.

    What This Means for Taper Strategy

    The priority when a patient has a history of one or more failed tapers is not simply to “try again with more conviction.” Three considerations follow from the kindling framework.

    First, pace should be even slower than standard. If a taper at 5% per month was intolerable last time, restarting at 5% per month is not a reasonable plan. Starting at 2.5% or lower, with hyperbolic reductions that decrease as the dose falls, is the pattern most consistent with the Maudsley Deprescribing Guidelines’ approach to patients with complicated histories.

    Second, stabilization before reduction is not a sign of failure. Patients who have kindled often need weeks to months at a stable dose before they can tolerate any further reduction. This is not time wasted; it is time during which the nervous system is not being re-provoked into another withdrawal episode. A taper that does not move for two months in a kindled patient is a better outcome than a taper that moves quickly and fails again.

    Third, the temptation to abandon a slow taper for a faster alternative is particularly dangerous in this population. The patient who has already failed one rapid detox is the patient whose next rapid detox is most likely to produce severe protracted harm. The arithmetic does not improve with repetition.

    Managing a Kindled Patient

    Several practical principles apply.

    Switch to a longer-acting agent if feasible. Interdose withdrawal on short-acting benzodiazepines is itself a form of micro-withdrawal and, in a kindled patient, should be minimized. A carefully executed Ashton-style substitution to diazepam can stabilize the interdose period before tapering resumes. The Maudsley Deprescribing Guidelines offer refined substitution ratios and a more cautious approach for complex cases.

    Use liquid or compounded formulations when the dose becomes too low for commercially available tablet fractions. Precision matters more in kindled patients; a 12.5% dose reduction is different from a 10% reduction at these dose levels, and approximate cutting produces approximate results.

    Hold the dose through exacerbations. A kindled patient in a symptom flare who reduces dose anyway is likely to worsen. Holding — sometimes for weeks — is usually the correct move.

    Coordinate with a clinician who will not push. The single most common path to repeated kindling is a prescriber who interprets the patient’s reasonable request to slow down as non-adherence and continues to move the dose anyway. A collaborative taper is a kindling-reducing intervention in itself.

    A Note on Patients Who Have Already Kindled

    Patients in this category often arrive having been told that their severe symptoms on prior attempts were psychosomatic, psychiatric, or reflective of underlying personality features. The kindling framework reframes the same clinical observation in neurobiological terms. This is not a minor point for the patient’s treatment or their engagement with a subsequent attempt; a patient who believes their problem is their psychology is harder to taper than a patient who understands they are managing a sensitized nervous system.

    The pattern of failed tapers making subsequent tapers harder is real, and it is the single strongest argument for getting the first attempt right. For patients who are past that point, the work now is to approach the next attempt with enough caution to keep it from becoming another data point in the kindling series.

  • Why Rapid Benzo Detox Programs Fail

    Why Rapid Benzo Detox Programs Fail

    Rapid benzodiazepine detoxification programs — inpatient protocols that promise discontinuation from a long-term benzodiazepine prescription in three to seven days, often with flumazenil infusion or heavy sedation — are advertised aggressively to patients who are miserable, desperate, and frequently dismissed by their regular prescribers. They fill a real void. They also routinely produce the exact outcome they promise to avoid: prolonged, severe withdrawal that can persist long after discharge and, in some cases, evolve into benzodiazepine-induced neurological dysfunction (BIND), the protracted syndrome described by Ritvo and colleagues in 2023.

    The core problem is a category error. Detox is a meaningful intervention for substances with predictable, self-limited withdrawal courses — alcohol and opioids being the primary examples. Benzodiazepine physiology is not in that category, and treating it as if it were is the pharmacologic source of the harm.

    How Rapid Detox Programs Are Structured

    Models vary, but the common format is brief inpatient admission (typically three to seven days) during which the patient’s benzodiazepine is stopped abruptly. Symptom control is attempted with adjuncts: clonidine, gabapentin, antiemetics, propofol or other sedatives, and in some programs flumazenil infusion. Flumazenil, a benzodiazepine receptor antagonist, is positioned in marketing material as a mechanism to “reset” receptor function. It is an FDA-approved agent for benzodiazepine overdose reversal; its use in detox is off-label, with limited evidence and a known risk of seizures.

    Programs frequently emphasize rapid return to normal function and discharge with minimal medication. What the discharge summary does not usually convey is that benzodiazepine withdrawal has a course measured in months, not days, and that acute symptom suppression during an inpatient stay has very little bearing on what happens three, six, or twelve weeks later.

    Why the Pharmacology Does Not Support It

    Long-term benzodiazepine exposure produces adaptations at the GABA-A receptor complex: downregulation, subunit composition shifts, and altered sensitivity. These changes take weeks to months to reverse, and the trajectory is not linear. Abrupt cessation unmasks the adaptation without any compensatory mechanism to absorb it, producing a state of GABAergic insufficiency in a nervous system that has been operating with external GABA amplification for sometimes years. Seizure risk is the most visible acute consequence; the less visible and more common outcome is a withdrawal course that extends far beyond the inpatient stay.

    Kindling is the second pharmacologic concern. Repeated cycles of benzodiazepine withdrawal — a first failed detox, resumption, another attempt — appear to lower the threshold for severe withdrawal on each subsequent attempt. Patients who have failed one rapid detox are often harder to taper successfully than patients who have never attempted one, and the rapid detox model almost guarantees a failed attempt.

    The Ashton Manual, first published by Professor C. Heather Ashton in 1999 and revised in 2002, lays out the alternative that every subsequent evidence-based framework — including the Maudsley Deprescribing Guidelines (Horowitz and Taylor, 2024) — has reaffirmed: slow, individualized dose reduction over months, with the pace set by the patient’s symptoms rather than by a fixed schedule. The Maudsley framework formalizes hyperbolic tapering: reductions that get proportionally smaller as the dose gets lower, reflecting the non-linear relationship between dose and GABA-A receptor occupancy.

    What the Evidence Looks Like

    There are no randomized trials supporting rapid detox as superior to gradual tapering for long-term benzodiazepine users. The published literature on flumazenil infusion consists primarily of case series and open-label studies, generally without follow-up long enough to detect protracted withdrawal or BIND. By contrast, the evidence for slow, patient-paced tapering is accumulated across decades of clinical experience documented in the Ashton Manual, the work of the Benzodiazepine Information Coalition, multiple published guidelines, and the recent formalization of hyperbolic tapering in the Maudsley guidelines.

    The absence of a rigorous evidence base for rapid detox is itself informative. Were these programs producing sustained remission at rates competitive with gradual tapering, the trials would exist. The programs continue to operate because they fill a demand, not because they survive clinical scrutiny.

    What Patients End Up With

    The clinical presentation after a failed rapid detox is recognizable. Patients arrive in protracted withdrawal weeks to months after discharge — sometimes reinstated on benzodiazepines at lower doses, sometimes not — with intensified symptoms, sleep architecture damage, sensory hypersensitivity, autonomic instability, and a course that now requires substantially more careful management than would have been needed had a slow taper been offered in the first place. A meaningful subset develop features consistent with BIND and face recovery timelines of a year or more.

    The economic picture compounds the clinical one. Rapid detox programs are typically not covered by insurance, and out-of-pocket costs can reach tens of thousands of dollars. Patients who have paid for an unsuccessful detox often have limited resources for the subsequent care that the failed detox makes necessary.

    The Evidence-Based Alternative

    Patients considering a rapid detox program are best served by a different approach: a careful, individualized, hyperbolic taper conducted with a clinician willing to set the pace by symptom tolerance rather than calendar. For patients whose current prescribers will not provide this, options include seeking out clinicians who specifically work with benzodiazepine tapering, requesting a liquid or compounded formulation to permit fine dose adjustments, and using the Ashton Manual and Maudsley Deprescribing Guidelines as reference documents in visits.

    This takes longer. It is also the approach with the evidence behind it.

    A Practical Caveat

    None of the above is an argument against inpatient care in selected situations. Patients with active suicidal ideation, intractable seizures, unstable comorbid illness, or safety concerns at home can benefit from hospitalization during a taper. But the taper still needs to be a taper. Hospitalizing a patient to enable a slow, monitored reduction is a different intervention from hospitalizing them to enable a rapid discontinuation. The first is good care. The second is the pattern that produces most of the cases clinicians familiar with BIND end up treating.